Currently no vaccines are licensed for Neisseria gonorrhoeae prevention although observational studies suggest the meningococcal B (4CMenB) vaccine may reduce gonorrhea risk. We conducted a multicentre, randomised, double-blind, placebo-controlled trial (GoGoVax) to assess 4CMenB efficacy against gonorrhoea in men who have sex with men at high risk of infection.
Light refreshments will be available from 12:30pm for in-person attendees. Registrations essential.
| Kate Seib
Professor Kate Seib is an NHMRC Leadership Fellow at the Institute for Biomedicine and Glycomics at Griffith University. Her research focuses on understanding virulence mechanisms and vaccine development for human mucosal pathogens including Neisseria gonorrhoeae and Neisseria meningitidis. She was involved in the development of the meningococcal vaccines 4CMenB, and has led two clinical trials to evaluate its ability to provide cross protection against gonorrhoea. |
Opinions expressed in the Kirby Institute Seminar Series are solely those of the speaker and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.
